Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.

Item

http://www.wikidata.org/entity/Q35796011

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Management of 3-aminopyridine- ...... one-induced methemoglobinemia.

@ast

Management of 3-aminopyridine- ...... one-induced methemoglobinemia.

@en

type

Item

label

Management of 3-aminopyridine- ...... one-induced methemoglobinemia.

@ast

Management of 3-aminopyridine- ...... one-induced methemoglobinemia.

@en

prefLabel

Management of 3-aminopyridine- ...... one-induced methemoglobinemia.

@ast

Management of 3-aminopyridine- ...... one-induced methemoglobinemia.

@en

P1476

Management of 3-aminopyridine- ...... zone-induced methemoglobinemia

@en

P2093

Charles A Kunos

http://www.w3.org/2001/XMLSchema#string

Charles L Hoppel

http://www.w3.org/2001/XMLSchema#string

Stephen T Ingalls

http://www.w3.org/2001/XMLSchema#string

P2860

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine

Structure and function of the radical enzyme ribonucleotide reductase

Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.

Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein

Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers

Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate

P304

145-150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.11.147

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tomas Radivoyevitch

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221833545

http://www.w3.org/2001/XMLSchema#string

P698

22335579

http://www.w3.org/2001/XMLSchema#string

P932

3292053

http://www.w3.org/2001/XMLSchema#string